AbbVie invests $195 million to expand API manufacturing in North Chicago, boosting U.S. production of neuroscience, immunology & oncology drugs. Part of a $10B U.S. investment plan for pharma innovation.
New North Chicago Facility to Boost Domestic API Production for Neuroscience, Immunology & Oncology Drugs
North Chicago, IL – Global biopharmaceutical leader AbbVie has announced a $195 million investment to expand its active pharmaceutical ingredient (API) manufacturing capabilities at its North Chicago, Illinois facility. This move reinforces AbbVie’s commitment to strengthening U.S. pharmaceutical supply chains and advancing production of critical medicines in neuroscience, immunology, and oncology.
Key Highlights of AbbVie’s Expansion
1. Investment & Strategic Focus
- Total Investment: $195 million (part of AbbVie’s broader $10 billion U.S. manufacturing commitment)
- Location: North Chicago, Illinois
- Focus Areas:
- Chemical synthesis expansion for API production
- Next-gen neuroscience, immunology & oncology drugs
- Domestic supply chain resilience
2. Project Timeline
- Construction Start: Fall 2025
- Expected Operational Date: 2027
- Long-Term Goal: Scaling U.S. production of APIs, drug products, peptides & medical devices
3. Leadership Statement
Robert A. Michael, Chairman & CEO, AbbVie:
“This expansion ensures U.S. leadership in pharmaceutical innovation while delivering next-generation medicines that transform patient lives. Over the next decade, we will continue investing in domestic API and drug manufacturing to support medical breakthroughs.”
Why This Expansion Matters?
✅ Reduces Reliance on Foreign API Imports – Strengthens U.S. drug supply security
✅ Supports Cutting-Edge Therapies – Expands production for neurology, cancer & autoimmune treatments
✅ Creates High-Skilled Jobs – Boosts Illinois’ biopharma workforce
✅ Aligns with National Health Priorities – Ensures stable access to critical medications
AbbVie’s Broader U.S. Investment Plan
- $10+ billion committed to U.S. manufacturing over the coming years
- Focus areas:
- API production
- Drug formulation & packaging
- Peptide & medical device manufacturing
What’s Next?
🔹 Construction begins Fall 2025
🔹 Hiring for specialized pharma manufacturing roles
🔹 Future expansions in U.S. biopharma infrastructure